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Abstract
Background: Randomised clinical trials (RCTs) are the gold standard for evaluating new cancer treatments. They
are, however, expensive to conduct, particularly where long-term follow-up of participants is required. Tracking
participants via routine datasets could provide a cost-effective alternative for ascertaining follow-up information
required to evaluate disease outcomes. This project explores the potential for routine data to inform cancer trials,
using, the historical National Cancer Data Repository (NCDR) for English NHS sites and, for validation, mature data
available from the TACT trial.
Methods: Datasets were matched using patients’ NHS number, date of birth (dob) and name/initials. Demographics,
clinical characteristics and outcomes were assessed for agreement and completeness. Overall survival was compared
between NCDR and TACT.
Results: A total of 3151 patients underwent linkage; 3047 (96.7%) of which had matched records. Extensive cleaning
was required for some registry data fields, e.g. cause of death, whilst others had large amounts of missing data, e.g.
tumour size (22.1%). Other data had high levels of matching such as dob (99.6%) and date of death (89.6%). There was
no evidence of differential survival rates (8-year survival: TACT = 75% (95% CI 73, 76); NCDR = 76% (95% CI 74, 77)).
Conclusions: Data quality and completeness requires improvement before routine data could be used for RCTs.
Introduction of new routine datasets, including COSD, is welcomed although reporting of disease-recurrence events
remains a concern. Prospective validation of such datasets is required before RCTs can confidently switch patient
follow-up to utilise routinely collected NHS-based data.
TACT Trial registration: Clinicaltrials.gov NCT00033683, registered on 9 April 2002; ISRCTN79718493, registered on 1
July 2001.
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Background
Randomised clinical trials (RCTs) form the gold standard
methodology to determine the efficacy and effectiveness
of new medical treatments. The primary endpoint in the
majority of phase III trials in early breast cancer,
disease-free survival, is typically analysed after a follow-
up of approximately 5 years from randomisation al-
though patients remain at risk of disease relapse and
subsequent death from disease for many years thereafter.
Unfortunately, partly due to cost and resource implica-
tions, there is an increased tendency to curtail follow-up
beyond 5 years once the principal objective has been
achieved [1]. However, if clinical trial follow-up does not
continue beyond 5 years late recurrences and toxicities
would not become apparent especially in patients sur-
viving beyond 10–15 years. Meta-analyses of thousands
of clinical trial patients by the Early Breast Cancer
Trialists’ Collaborative Group (EBCTCG) have shown
that disease-related events continue to occur out to at
least 15 years [2, 3]. Thus terminating follow-up after
5 years potentially provides an incomplete understanding
of treatment benefits and risks may go undetected in these
otherwise healthy individuals.
Traditionally, clinical trial data collection requires each
participating hospital to obtain data, retrieve missing in-
formation and forward to the coordinating clinical trials
unit for analysis. The entire process can be time-
consuming and labour-intensive both for hospital staff
and the clinical trials units. In addition, it requires pa-
tients to either continue returning to hospitals many
years after their treatment has been completed or to be
reminded of their cancer diagnosis by telephone call
from a research nurse [1].
Routine sources of data capture are the information
regarding individual patients’ cancer diagnosis, treatment
and outcomes collected by individual hospitals. These
sources include data submitted by National Health Service
(NHS) providers and Healthcare Quality Improvement
Partnership (HQIP) commissioned national cancer audits.
These data sources have not been designed specifically for
clinical trials use, however, may provide a potentially cost-
effective alternative to hospital-based clinical trial follow-
up. In England, the National Cancer Intelligence Network
(NCIN), established in 2007 and now part of Public
Health England’s National Cancer Registration and
Analysis Service [4], developed the National Cancer Data
Repository (NCDR). At the time, this retrospectively com-
bined data from eight English Cancer Registries, Office
for National Statistics mortality data and the Hospital
Episodes Statistics (HES) dataset. However, before
changing clinical trial follow-up procedures, trialists
need confidence that the data provided by routine
sources captures the information required to answer
the research question and that the datasets are of
sufficient quality and completeness to replace current
data collection practices. As a first step, it is helpful to
establish the baseline data linkage capabilities using
routine data as historically collected to understand how
new and revised versions of these datasets can be struc-
tured to provide the necessary added-value to allow the
switch to more efficient data capture. To do this, a pro-
ject, initiated on behalf of the NCRI Breast Clinical
Studies Group, to retrospectively link mature follow-up
data from the Taxotere and Adjuvant ChemoTherapy
(TACT) randomised clinical trial in women with early
breast cancer [5, 6] with the NCDR was conducted to
assess the baseline viability of linkage with routine
datasets.
Methods
The UK TACT trial (CRUK01/001) randomly assigned
4162 women with node-positive or high-risk node-nega-
tive early breast cancer to sequential docetaxel after
anthracycline chemotherapy [Fluorouracil, epirubicin,
cyclophosphamide - taxotere (FEC-T)] or standard
anthracycline chemotherapy of similar duration [FEC
or epirubicin – cyclophosphamide, methotrexate, fluo-
rouracil (E-CMF)] between February 2001 and July
2003 [5, 6]. (Consort diagram for the publication of the
principal TACT results is shown in Fig. 1). Data from
the 3151 TACT patients from English centres were
retrospectively linked to the NCDR, containing details of
cancer diagnoses, demographic information, in-patient
and day-case episodes, diagnoses and operations. The
linkage was based on a snapshot of TACT data extracted
on 25 November 2011 when median follow-up in the trial
database for all patients was 97.5 months interquartile
range (IQR) (87.6; 107.4); the NCDR includes registry data
up to January 2011 and HES data to March 2010 (Fig. 2).
TACT patients had provided informed consent for access
to routine medical records; therefore, no additional ap-
proval was required to receive data from NCIN.
TACT patients were matched to the routine datasets
using their unique NHS number. The initial match was
then confirmed using date of birth. Minor errors in birth
records (different day or month) were ignored if the pa-
tient’s name (routinely collected in TACT) matched.
Date of surgery as reported in TACT was then used to
define when a patient comes under observation in the
NCDR data. HES data presented multiple observations
per patient depending the number of hospital out-
patient/inpatient visits. A similar issue was found in can-
cer registry data with the same patient presenting at
least two different diagnosis dates. An important stage
was then the identification of a unique observation per
patient. The general rule to identify the most appropri-
ate patient/observation was to consider for each patient
the nearest observation to the date of surgery provided
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in TACT. The record closely matching these data was
retained and included in the final NCDR dataset to pro-
duce one record per patient. The key variables to iden-
tify the correct record were agreed by the project team
as the date of diagnosis in the cancer registry dataset
and date of hospital admission in HES. Data cleaning
and standardisation of data across the data sources was
undertaken before information was used for further ana-
lysis. This included validation checks, error detection and
correction (e.g. patient identifiers mismatching, incorrect
classifications (e.g. male)) investigation of outliers, incom-
plete and incorrectly formatted data (e.g. inconsistent date
formatting, date of operation not always available) and
establishing a consistent coding system for key variables
(e.g. nodal status, tumour size (millimeter not centi-
metre)). Data cleaning was conducted objectively where
possible (e.g. date formatting), otherwise resolution of in-
dividual issues were achieved by consensus of the project
team. The level of agreement between NCDR/HES and
TACT for key fields (date of death, cause of death and pa-
tient’s clinical status) was reported and overall survival
and survival rates were compared using standard survival
analysis methods (e.g. Cox proportional hazards model).
As distinct recording of breast cancer recurrence was
not available in the NCDR, an attempt was made to see
if the recurrences recorded in TACT dataset could be
matched with a suitable “proxy” event in NCDR. It is
known that a patient will only have oncological
2074 received allocated treatment
388 discontinued treatment early...
39 before 349 after
cycle 5 cycle 5
Toxicity/illness 14 190
Patient choice 10 118
Centre issues 0 3
Progression/died 11 8
Other 4 30
Followed-up
2089 randomised
378 (18%) died
1608 (77%) complete follow-up
65 (3%) >15 months since last seen
38 (2%) withdrawn or lost to follow-up
2073 allocated to FEC-D
(FEC centres: 1258
E-CMF centres: 815)
2061 received allocated treatment
390 discontinued treatment early...
128 before 292 after
cycle 5 cycle 5
Toxicity/illness 46 218
Patient choice 52 29
Centre issues 4 0
Progression/died 6 0
Other 20 15
2089 allocated to control group
(FEC centres: 1265
E-CMF centres: 824)
4162 patients randomised
Efficacy
analysis
population
Safety
analysis
population
Followed-up
2073 randomised
374 (18%) died
1583 (76%) complete follow-up
87 (4%) >15 months since last seen
29 (2%) withdrawn or lost to follow-up
9 ineligible (unevaluable)
Metastatic disease 6
Bilateral cancer 1
Previous breast cancer 1
Synchronous ovarian cancer 1
6 ineligible (other protocol violation)
Abnormal liver function 2
Reduced cardiac function 2
Poor wound healing 1
Incomplete excision 1
7 ineligible (unevaluable)
Metastatic disease 5
Bilateral cancer 1
DCIS only 1
8 ineligible (other protocol violation)
Abnormal liver function 2
Reduced cardiac function 1
Poor wound healing 3
Incomplete excision 1
Leucopenia 1
15 did not start
allocated treatment...
Ineligible (unevaluable) 6
Ineligible (protocol violator) 5
Received FEC-D in error 1
Patient choice 3
12 did not start
allocated treatment...
Ineligible (unevaluable) 4
Ineligible (protocol violator) 4
Received E-CMF in error 3
Patient choice 1
Fig. 1 CONSORT diagram for the publication of the principal results of the TACT trial [6]. E-CMF epirubicin – cyclophosphamide, methotrexate,
fluorouracil, FEC-T fluorouracil, epirubicin, cyclophosphamide – taxotere, TACT Taxotere and Adjuvant ChemoTherapy
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intervention (e.g. chemotherapy, surgery) following their
primary treatment if there is evidence of recurrence and
therefore the project team agreed that any oncological
intervention approximately 1 year after primary treat-
ment has been completed was to be explored as a poten-
tial indicator of recurrence. In addition, an exploratory
multivariable logistic regression model was developed to
see if there were any factors that predicted agreement
between the TACT and NCDR datasets for distant recur-
rence. A forward stepwise selection method was used to
select variables for inclusion within the model. Variables
were included if they were statistically significant at the
1% level. The candidate covariates were year of relapse,
site of relapse and centre. For modelling of centre-only
data from centres with > 10 patients were included.
All analyses were conducted using Stata (version 12.1)
(StataCorp, College Station, TX, USA).
Results
Record linkage was high with 3047 (96.7%) patients suc-
cessfully identified in NCDR and/or HES using the NHS
number. Inevitably, when confirmation of patients’ re-
cords using birth date and name, and identification of
the observation period to produce one row per patient
was conducted, the success rate was slightly lower (3036
patients, 96.4%) (Fig. 3).
Level of agreement between TACT dataset and NCDR
was excellent for demographic data. Staging data at diag-
nosis, e.g. nodal status and tumour size, showed poor
concordance, primarily as a result of missing data
(Table 1). Other reasons for discordance were potentially
attributable to measurement unit errors (i.e. millimetre
versus centimetre in recording tumour size) and likely
misunderstanding of the data collection requirements
and/or patient notes for certain data items by the data
entry clerk at site, for example confusion between the
number of nodes involved versus number of nodes
examined; the latter, perhaps supported by the fact that
another clinical detail, laterality of the tumour, was very
well recorded. However, when considering if the level of
discordance in the staging data changed clinical risk
stratification, the impact was minimal with 20/1665
(1.2%) patients’ nodal status changing from positive to
negative or vice versa and 31/2286 (1.4%) patients’
tumour size changing from ≤ 2 cm to > 5 cm or
from > 5 cm to ≤ 2 cm.
Date of death was recorded for 748 patients in TACT
dataset; nine deaths occurred after the last NCDR data
extract and therefore were censored. Eighteen patients
who had died according to the TACT dataset had no
death recorded in the NCDR. In addition, the Cancer
Registry contained an extra 27 death notifications that
were not available in the TACT dataset. Despite these
discrepancies, there was no evidence of a difference in
overall survival between the two datasets (Fig. 4). Eight-
year survival rates were 75% (95% CI 73, 76) in TACT
dataset and 76% (95% CI 74, 77) in NCDR, respectively.
Of the 2929 TACT patients who were correctly identi-
fied in NCDR and for whom HES data was available,
898 (30.7%) had had a disease-free survival (DFS) event
(140 local recurrence, 691 distant recurrence or 67 new
breast second primary cancer) reported in the TACT
dataset. Any DFS event in TACT dataset after the
reporting date of the HES dataset was noted but not
considered a discrepancy case (2 local, 22 distant recur-
rences and 1 second primary cancer). The level of
matching between a DFS event in TACT dataset and a
hospital episode suggesting relapse reported in NCDR
was 71.0% (98 events) for local recurrence, 63.5% (425
events) for distant recurrence and 81.8% (54 events) for
new breast second primary cancer (Table 2), precluding
survival analysis based verification of the trial’s primary
endpoint. For distant recurrences reported, a multivari-
able model suggested that distant recurrences were more
Fig. 2 Time period of datasets. HES Hospital Episode Statistics, TACT Taxotere and Adjuvant ChemoTherapy
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Table 1 Agreement between TACT dataset and NCDR extraction
Variables NCDR component dataset Agreement, n (%) No Agreement, n (%) Missing, n (%)
Date of birth, (n = 3047) Cancer Registry and HES 3036 (99.6) 11 (0.4) –
Date of surgerya, (n = 2929) HES 2892 (98.7) 37 (1.3) –
Date of deathb, (n = 739) Cancer Registry 662 (89.6) 59 (8.0) 18 (2.4)
Nodal statusc, (n = 2941) Cancer Registry 1709 (58.0) 26 (1.0) 1206 (41.0)
Nodes involvedc, (n = 2941) Cancer Registry 1581 (53.8) 85 (2.8) 1275 (43.3)
Nodes examinedc, (n = 2041) Cancer Registry 1469 (50.0) 229 (7.8) 1238 (42.2)
Tumour sizec, (n = 2941) Cancer Registry 2075 (70.6) 211 (7.2) 651 (22.1)
Side of tumourc, (n = 2941) Cancer Registry 2850 (96.9) 46 (1.6) 44 (1.5)
Tumour gradec, (n = 2941) Cancer Registry 2181 (74.5) 668 (22.8) 79 (2.7)
TACT Taxotere and Adjuvant ChemoTherapy, NCDR National Cancer Data Repository, HES Hospital Episode Statistics
aMatches using NHS number, date of birth and patient’s name and surname
bDenominator = number of deaths in TACT once linked to the Cancer Registry
cMatches using NHS number, date of birth and patient’s name. Clinical status assessed within 90 days from date of surgery as entered in TACT
Fig. 3 Success of linkage between TACT dataset and NCDR extraction. HES Hospital Episode Statistics, NHS National Health Service, TACT Taxotere
and Adjuvant ChemoTherapy
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likely to be identified in the NCDR dataset if they in-
cluded metastases to the brain. Conversely, disagreement
was more likely if the relapse was recent or if the patient
had lung metastases. Degree of agreement also varied
between centres (Table 3).
Discussion
The retrospective linkage of the TACT dataset and
NCDR has shown that where data exist, routine data is
of reliable quality, i.e. agreement > 70% for the majority
of variables matched. Some of the issues related to using
traditional routine datasets include inherent biases such
as the amount of missing data, in particular, staging and
recurrence details and also the time lag in receiving data.
This can result in informative censoring. Within the
context of this project we are matching within a pre-
defined population of trial patients and not attempting
to extrapolate to the general population to estimate inci-
dence rate thus some of the biases known to occur in
routine datasets may be less problematic for use within
clinical trials.
In relation to data characterisation, centres may also
benefit from further guidance to avoid misunderstanding
of data entry requirements. Lack of standardisation
across registries was also problematic requiring the data
to be cleaned prior to starting any analysis; the most time
consuming part of this validation exercise. Examples in-
clude data recorded in the wrong fields, e.g. clinical stage
recorded as pathological stage, and inconsistent data for-
mats within a field (coding versus free text). However,
once cleaned, comparisons of overall survival, one of the
key TACT endpoints, show similar conclusions are drawn
from basic outcome data whether using routine data for
follow-up versus traditional data collection methods. Little
can be said about cancer recurrence, which is often the
primary endpoint of phase III cancer RCTs, as data were
not consistently available in NCDR at the time and there-
fore is an unfair comparison. However, a 70% ascertain-
ment rate for an endpoint would not under other
circumstances be considered acceptable for a clinical trial,
and whilst no evidence of bias was observed, it would be
difficult to rule out. Therefore, availability of properly
TACT
5 year survival rate: 83% 95%CI(81, 84)
8 year survival rate: 75% 95%CI(73, 76)
NCDR
5 year survival rate: 83% 95%CI(81, 84)
8 year survival rate: 76% 95%CI(74, 77)
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Fig. 4 Difference in overall survival between TACT dataset and NCDR extraction (red = NCDR data, blue = TACT data). NCDR National Cancer Data
Repository, TACT Taxotere and Adjuvant ChemoTherapy
Table 2 Identification of TACT-reported disease-free survival events in NCDR
Local recurrence Distant recurrence New breast disease
(N = 140) (N = 691) (N = 67)
Agreementa 98 (71.0%) 425 (63.5%) 54 (81.8%)
Event reported in TACT but not in NCDR 17 76 2
Disagreement in number of sites and/or diagnosis time 23 168 10
Event occurred after 31 March 2010 (HES extract date) 2 22 1
aDenominator excludes events occurring after 31 March 2010 (HES extract date). TACT Taxotere and Adjuvant ChemoTherapy, NCDR National Cancer Data
Repository, HES Hospital Episode Statistics
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specified recurrence data is a prerequisite for the future
utility of routine datasets.
Recently, new national datasets have been introduced
to improve the quantity and quality of cancer informa-
tion collected including specific details of radiotherapy
and systemic treatments and a new minimum core data-
set – the Cancer Outcomes and Services Dataset
(COSD) – capturing basic information on treatment,
diagnosis and death that now includes details on cancer
recurrence, a key outcome for cancer RCTs [7]. The
resulting linked data aims to allow each patient’s treat-
ment pathway to be mapped from diagnosis to cure or
death with emphasis relating to collecting cancer-
specific information. Given our experience to date, the
new information on recurrence, e.g. date of recurrence,
required to make the switch to routine viable for cancer
clinical trials, should be reasonably captured in the
COSD. However, site of recurrence will not be recorded
so easily, therefore analyses exploring patterns of relapse
and more specific recurrence-related endpoints, such as
time to distant recurrence, represent a considerable limi-
tation for its utility.
The strength of this study is that this was a large
multicentre study and so routine data will have been col-
lected from a number of different hospitals across
England giving a realistic impression of the quality and
variability of data available. Unfortunately, at the time of
this study the newer datasets were not available. This
study provides a useful baseline from which to compare
the new datasets; however, the matching process using
the newer datasets will be required.
Now that a baseline has been established, the next
phase is to prospectively evaluate the new routine data-
sets with contemporary trial data. Working with the
National Cancer Registration and Analysis Service
(NCRAS) within Public Health England, the ICR Clinical
Trials and Statistics Unit (ICR-CTSU) will help validate
the COSD, the Systemic Anti-Cancer Therapy (SACT)
dataset, radiotherapy dataset (RTDS) and HES using data
initially from the TACT2 (ISRCTN68068041) [8], POETIC
(ISRCTN63882543), IMPORT HIGH (ISRCTN47437448)
and FAST FORWARD (ISRCTN19906132) breast cancer
trials.
This prospective validation study will identify whether
routine datasets are of sufficient standard to replace
traditional data collection methods. The objectives are
to identify and quantify the number of trial participants
within each relevant dataset; conduct an objective as-
sessment of routine data completeness, validity, and
consistency with trial data; a cross-comparison of trial
baseline and treatment data and emerging disease-
related outcome data; collection of long-term safety data
and identifying the representativeness of trial patients
versus general population matched to the trial’s main
criteria (e.g. tumour characteristics). After investigating
the data from breast cancer trials, the plan is to extend
beyond breast cancer into other disease areas, e.g. pros-
tate, once the project is fully established. The aim is to im-
prove quality and completeness of routine data via a two-
way data exchange whilst also allowing a longitudinal as-
sessment to see when these datasets may be of a sufficient
standard, particularly the data relating to recurrence, to
replace traditional data collection methods for RCTs.
Using routine datasets as an alternative for clinical
trial follow-up data collection shows promise but the
switch is unlikely to happen in the near future. Phase III
clinical trials are initiated with the aim of influencing
clinical practice, therefore follow-up data needs to be
complete, contemporary and of high quality to ensure
Table 3 Logistic regression model identifying factors for distant
recurrence agreement between TACT and routine datasets
Odds ratio 95% CI P value
Year relapse reported 0.88 0.80, 0.97 0.01
Distant relapse site = lung 0.61 0.38, 0.98 0.04
Distant relapse site = brain 2.96 1.29, 6.77 0.01
Centre [A] 0.28 0.07, 1.09 0.07
Centre [B] 0.41 0.06, 2.98 0.38
Centre [C] 1.31 0.19, 8.83 0.78
Centre [D] 0.18 0.03, 0.99 0.05
Centre [E] 0.29 0.05, 1.58 0.15
Centre [F] 0.30 0.06, 1.45 0.14
Centre [G] 0.34 0.06, 1.83 0.21
Centre [H] 0.04 0.01, 0.23 < 0.001
Centre [I] 0.05 0.01, 0.29 0.001
Centre [J] 0.07 0.02, 0.33 0.001
Centre [K] 0.28 0.05, 1.52 0.14
Centre [L] 0.31 0.05, 1.92 0.21
Centre [M] 0.37 0.06, 2.29 0.29
Centre [N] 0.37 0.09, 1.61 0.19
Centre [O] 0.07 0.01, 0.43 0.004
Centre [P] 0.23 0.05, 1.19 0.08
Centre [Q] 0.66 0.09, 4.60 0.68
Centre [R] 0.06 0.01, 0.37 0.002
Centre [S] 0.14 0.03, 0.58 0.007
Centre [T] 0.19 0.04, 0.84 0.03
Centre [U] 0.11 0.02, 0.60 0.01
Centre [V] 0.08 0.02, 0.39 0.002
Centre [W] 0.15 0.04, 0.60 0.007
Centre [X] 0.07 0.01, 0.38 0.002
Centre [Y] 0.10 0.02, 0.50 0.005
OR < 1 imply distant recurrence less likely to be identified in NCDR dataset
compared to gold standard TACT dataset. Individual centres included in the
model have been anonymised. TACT Taxotere and Adjuvant ChemoTherapy
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results are robust. Missing data is a key problem for rou-
tine data, particular of registry data, and increased
standardisation would enhance accessibility. This can be
achieved in part through increased training of hospital
coding staff and the switch to the single shared registry
system, English National Cancer Online Registration
Environment (ENCORE).
As clinical trials are often run throughout the whole of
the UK and beyond, another recommendation would be
for the NCRAS to integrate data from the devolved na-
tions to allow access to UK-wide registry data in one
application process. Currently, this requires separate
applications and it is not obvious to clinical trial re-
searchers how to gain access to these datasets.
If routine data was adopted in a future clinical trial in
the place of centre-based follow-up we would recommend
that data ‘cleaning’ has an appropriate level of quality con-
trol checking as part of the trial’s standard data monitoring
plan. This needs to be efficient and proportionate to the
risk of the trial. For example, trials of an investigational
medicinal product used in an unlicensed indication would
require a higher amount of checking. Similarly, fields re-
lated directly to primary endpoint evaluation would require
more validation. Data monitoring plans should be agreed
by the trial team as early as possible. For routine data we
recommend both “in house” verification of data as part of
central statistical data monitoring whilst allowing the pos-
sibility of direct contact with centres for clarification of sig-
nificant suspected systematic issues with data quality.
Using routine datasets to facilitate long-term follow-
up should reduce the burden on research teams in hos-
pitals allowing them to focus on higher-risk patients. In
addition, patients should benefit by avoiding unnecessary
follow-up visits. The resource saving may be less clear
for clinical trials units. While switching to routine data
use may reduce costs, the amount of time required to
clean, process and merge routine data (with either in-
house data collection or even datasets from other coun-
ties) may increase the workload substantially for the tri-
als unit data managers and statisticians.
Finally, routine data needs to be updated frequently to
be able to compete with the traditional data collection
methods. The lag time for availability of registry and
HES data in the NCDR dataset used for this validation
study meant that the most recent data available in TACT
could not be used for comparison. In addition, the time
taken to request, receive and process routine data will
need to be minimised to avoid delays in publishing a
practice-changing result which would counterbalance the
cost-effectiveness of the data collection method.
Conclusions
The overall aim for trialists, hospitals and patients is for
clinical trials to run more efficiently with a reduced
resource burden and this may be achieved by using rou-
tine data sources. Using routine data sources allows
centre staff to prioritise patients who require further
intervention for their cancer and allows clinical trials to
maximise information gathered to answer the research
questions within the trial design; thus ultimately improv-
ing patient care. By working with NCRAS to prospect-
ively validate the quality of routine data compared with
traditional methods we can identify whether routine data
can be used for clinical trial follow-up purposes in a
more timely manner.
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